Sangamo Therapeutics Inc (NASDAQ:SGMO)
| 9.98 Delayed Data As of Dec 04 |  +0.12 / +1.22%Today’s Change | 4.81 Today|||52-Week Range 13.20 | +19.24% Year-to-Date |
Latest SGMO News | Press Releases
| Pfizer (PFE) Begins Phase III Study on Hemophilia Candidate Nov 24 / Zacks.com - Paid Partner Content | This Company's New Approach Could Slash Gilead's Profit From HIV Drugs Nov 22 / MotleyFool.com - Paid Partner Content |
Today’s Trading
| Previous close | 9.86 |
| Today’s open | 9.91 |
| Day’s range | 9.80 - 10.01 |
| Volume | 80,096 |
| Average volume (3 months) | 1,575,358 |
| Market cap | $1.4B |
Data as of 3:59pm ET, 12/04/2020
Growth & Valuation
| Earnings growth (last year) | -20.44% |
| Earnings growth (this year) | -0.52% |
| Earnings growth (next 5 years) | -5.10% |
| Revenue growth (last year) | +21.29% |
| P/E ratio | NM |
| Price/Sales | 9.16 |
| Price/Book | 2.74 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| ADVMAdverum Biotechnolog... | -0.54 | -3.79% |
| CRTXCortexyme Inc | -9.31 | -19.42% |
| RGNXRegenxbio Inc | -0.07 | -0.18% |
| CHRSCoherus BioSciences ... | +0.33 | +1.77% |
Data as of 5:04pm ET, 12/04/2020
Financials
| Next reporting date | March 4, 2021 |
| EPS forecast (this quarter) | -$0.24 |
| Annual revenue (last year) | $102.4M |
| Annual profit (last year) | -$95.2M |
| Net profit margin | -92.93% |
Profile
Sector Health Technology |
Industry Biotechnology |
No executives to display |
Corporate headquarters Brisbane, California |
Forecasts
